Announcements Trials
Browse Landscape

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Observational 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 2934Neoplasms 174Lung Neoplasms 149Prostatic Neoplasms 116Ovarian Neoplasms 113Colorectal Neoplasms 106Triple Negative Breast Neoplasms 98Colonic Neoplasms 91Neoplasm Metastasis 74Melanoma 66Carcinoma, Non-Small-Cell Lung 64Pancreatic Neoplasms 63Carcinoma, Intraductal, Noninfiltrating 60Stomach Neoplasms 54Head and Neck Neoplasms 47Breast Cancer Female 45Lymphedema 42Uterine Cervical Neoplasms 40Breast Carcinoma In Situ 35Esophageal Neoplasms 34Cardiotoxicity 34Urinary Bladder Neoplasms 33Motor Activity 33Lymphoma 33Endometrial Neoplasms 33Breast Diseases 33Fatigue 30Rectal Neoplasms 28Breast Neoplasms, Male 28Multiple Myeloma 27

Interventions

trastuzumab deruxtecan 1Isovaleryl-CoA Dehydrogenase 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Observational × HER2 Overexpression × Breast × Clear all
NCT07035353 2025-06-25

A Real-world Clinical Study of T-DXd for the Treatment of Chinese Patients With HER2 Overexpressing and HER2 Underexpressing Advanced Breast Cancer

Tianjin Medical University Cancer Institute and Hospital

Not yet recruiting
200 enrolled
Breast

HER2 Overexpression

Data powered by HemOnc (CC BY 4.0) Colophon âš¡